Business Context and Reporting Period
Company: Boston Scientific Corporation (BSX)
Filing Type: Form 8-K (Current Report)
Date of Report: January 14, 2026
Event: Entry into a Material Definitive Agreement (Merger Agreement) to acquire Penumbra, Inc.
Key Financial Metrics and Transaction Terms
This filing details the terms of the proposed acquisition rather than Boston Scientific's standalone operating results for a specific period. Key financial terms of the transaction include:
- Consideration Structure: Penumbra shareholders may elect to receive either cash or Boston Scientific common stock.
- Cash Consideration: $374.00 per Penumbra share.
- Stock Consideration: 3.8721 Boston Scientific shares per Penumbra share.
- Proration Mechanism: The total consideration is capped such that 73.26% of Penumbra shares receive cash and 26.74% receive stock.
- Equity Award Treatment: Unvested options and RSUs will be converted into a mix of cash ($274.00 per share equivalent) and stock (1.0353 BSX shares per share equivalent).
- Termination Fees:
- Penumbra to pay Boston Scientific: $525,000,000 (if terminated for a superior proposal or change in recommendation).
- Boston Scientific to pay Penumbra: $900,000,000 (if terminated due to regulatory failure or restraint after stockholder approval).
Note: The filing text does not provide Boston Scientific's current revenue, profit, cash flow, or debt levels. These metrics are not disclosed in this specific 8-K.
Material Changes and Conditions
The primary material change is the execution of the Merger Agreement. The transaction is subject to several material conditions, including:
- Approval by a majority of Penumbra's outstanding shares.
- Receipt of requisite regulatory approvals (including HSR Act waiting periods) and absence of legal restraints.
- Effectiveness of the Form S-4 registration statement and NYSE listing approval for new shares.
- Accuracy of representations and warranties and absence of a Material Adverse Effect.
Guidance, Outlook, and Risks
Management Commentary: The filing includes standard forward-looking statements regarding the anticipated benefits of the transaction, integration plans, and expected financial results, but does not provide specific quantitative guidance or earnings projections in this document.
Risks and Contingencies:
- Regulatory Risk: Failure to obtain antitrust or other governmental approvals could result in the $900 million termination fee payable by Boston Scientific.
- Integration Risk: Challenges in integrating Penumbra's operations and achieving anticipated synergies.
- Market and Operational Risks: Economic conditions, currency fluctuations, supply chain disruptions, and clinical trial outcomes.
- Fiduciary Out: Penumbra's board retains the right to terminate the agreement to pursue a superior proposal under certain conditions.
Investor Verification Checklist
- Verify the final vote outcome of the Penumbra stockholder meeting.
- Monitor the status of regulatory approvals, specifically antitrust clearances under the Hart-Scott-Rodino Act.
- Review the upcoming Form S-4 Proxy Statement/Prospectus for detailed financial pro formas and risk factors.
- Assess the impact of the $900 million potential termination fee on Boston Scientific's liquidity if regulatory approval is denied.
- Confirm the final exchange ratio and cash/stock split based on the proration mechanism once the transaction closes.